Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies blood and spinal fluid in status epilepticus and dysimmune encephalitis

Collects blood and spinal fluid samples from people with severe seizures or immune-related encephalitis.

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
Paris, FranceSee the site
Trial code
Registry title
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
Status
Recruiting
People taking part
400 people, planned
Started
25 Nov 2020
Expected to end
1 Jun 2033
Type of study
Interventional, 3 groups
Treatments tested
  • Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
  • Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)
Record updated
22 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with status epilepticus, people with epilepsy linked to autoimmune brain inflammation, and a control group without these conditions.

Age
Groups 1 and 2: 2 years or older. Group 3 (control): 18 years or older.
Sex
All sexes can join.
Disease stage
Group 1: status epilepticus. Group 2: clinical signs of epilepsy linked to dysimmune (autoimmune) encephalitis. Group 3: no status epilepticus and no dysimmune encephalitis.
Earlier treatment
Group 2: people already treated with corticoids or IgIV cannot join.

Main reasons for not taking part

  • Pregnancy (known or clinically detected)
  • Deprived of liberty
  • Known neurodegenerative disease (Groups 1 and 3)
  • Already treated with corticoids or IgIV (Group 2)
  • Control group: status epilepticus, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhage or stroke

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Group 1:
  • Patients aged 2 years or above, with status epilepticus
  • Affiliation to a French social security system excluding "Aide Médicale" Etat (AME)
  • Patients or relatives have been informed and given free informed and written consent to participate
  • Patients under legal protection (guardianship, curatorship) or not; Group 2:
  • Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis
  • Affiliation to a French social security system excluding "Aide Médicale" Etat (AME)
  • Patients or relatives have been informed and given free informed and written consent to participate
  • Patients under legal protection (guardianship, curatorship) or not; Group 3:
  • Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis
  • Affiliation to a French social security system excluding "Aide Médicale" Etat (AME)
  • Patients or relatives have been informed and given free informed and written consent to participate
  • Patients under legal protection (guardianship, curatorship) or not

Who cannot take part

  • Patients with known neurodegenerative disease; Group 2:
  • Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke
  • Group 1:
  • Women with known or clinically detected pregnancy
  • Patient deprived of liberty
  • Women with known or clinically detected pregnancy
  • Patient deprived of liberty
  • Patients have been already treated by corticoids or IgIV; Group 3:
  • Women with known or clinically detected pregnancy
  • Patient deprived of liberty
  • Patients with status epilepticus

Where in France

  • Hôpital de la Pitié-SalpêtrièreParis, FranceContact: Vincent NAVARRO, PrTaking people

About the trial

What the trial wants to find out

COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune encephalitis as well as in control patients, to better understand the pathophysiology of these severe epileptic disorders.

The 3 groups in the trial

  • Group 1 : Status epilepticusOther group

    Treatment: Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)

  • Group 2 : Dysimmune encephalitisOther group

    Treatment: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)

  • Group 3 : Control patientsOther group

    Treatment: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
COLETTE : Study of the Pathophysiology of Status Epilepticus and Dysimmune Encephalitis and Identification of Valuable Biomarkers
Plain-language title
Studies blood and spinal fluid in status epilepticus and dysimmune encephalitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 May 2026